References
- Mul S. Ziek van de pillen [Sick of the pills]. Consumentengids. 2014;(6):16–19.
- Hunsel F, Waal S, Härmark L. The contribution of direct patient reported ADRs to drug safety signals in the Netherlands from 2010 to 2015. Pharmacoepidemiol Drug Saf. 2017;26(8):977–983.
- Rolfes L, van Hunsel F, van der Linden L, et al. The quality of clinical information in adverse drug reaction reports by patients and healthcare professionals: a retrospective comparative analysis. Drug Saf. 2017;40(7):607–614.
- Rolfes L, van Hunsel F, Taxis K, et al. The impact of experiencing adverse drug reactions on the patient’s quality of life: a retrospective cross-sectional study in the Netherlands. Drug Saf. 2016;39(8):769–776.
- Avery AJ, Anderson C, Bond CM, et al. Evaluation of patient reporting of adverse drug reactions to the UK ‘Yellow Card Scheme’: literature review, descriptive and qualitative analyses, and questionnaire surveys. Health Technol Assess. 2011;15(20):1–234.
- Härmark L, Raine J, Leufkens H, et al. Patient-reported safety information: a renaissance of pharmacovigilance? Drug Saf. 2016;39(10):883–890.
- The European Parliament and the Council of the European Union. Directive 2010/84/EU of the European parliament and the council of 15 December 2010. Off J Eur Commun. 2010;348:74–99.
- The European Parliament and the Council of the European Union. Regulations regulation (EU) no 1235/2010 of the European parliament and of the council of 15 December 2010. Off J Eur Commun. 2010;348:1–16.
- European Patients’ Academy on Therapeutic Innovation (EUPATI). What is EUPATI? 2014 [cited 2016 Jun 20]. Available from: https://www.eupati.eu/what-is-eupati/
- Nederlandse vereniging voor psychiatrie. Richtlijn ADHD bij volwassenen [Guideline ADHD in adults]. 2015 Jul [cited 2017 Dec 19]. Available from: http://www.nvvp.net/stream/richtlijn-adhd-bij-volwassenen-fase-1-diagnostiek-en-medicamenteuze-behandeling-2015
- MedDRA. Medical dictionary for regulatory activities. [cited 2017 Dec 19]. Available from: https://www.meddra.org/
- Netherlands Pharmacovigilance Centre Lareb. Lack of effect after substitution of methylphenidate prolonged-release. 2017 Nov [cited 2018 Apr 8]. Available from: https://www.lareb.nl/media/3116/signals_2017_methylfenidaat-substitutie-lack-of-effect-2.pdf
- College ter Beoordeling van geneesmiddelen (CBG). DHPC methylfenidaat HCL mylan retard. [cited 2018 Jul 17]. Available from: https://www.cbg-meb.nl/documenten/brieven/2015/07/16/dhpc-methylfenidaat-hcl-mylan-retard
- Dutch SmPC methylfenidaat Ritalin®. 2017 [cited 2018 Apr 8]. Available from: http://db.cbg-meb.nl/IB-teksten/h03957.pdf
- Dutch SmPC methylfenidaat Concerta®. 2018 [cited 2018 Apr 8]. Available from: https://db.cbg-meb.nl/IB-teksten/h28073.pdf
- Dutch SmPC dexamfetamine Amfexa®. 2016 [cited 2018 Apr 8]. Available from: https://db.cbg-meb.nl/IB-teksten/h110336.pdf
- Tuithof M, Ten Have M, van Dorsselaer S, et al. Prevalentie, persistentie en gevolgen van ADHD in de Nederlandse volwassen bevolking [Prevalence, persistence and consequences of ADHD in the Dutch adult population]. Tijdschr Psychiatr. 2014;56(1):10–19.